There are currently 61 clinical trials in Lancaster, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including Lancaster General Hospital, Urological Associates Of Lancaster, Lancaster Urology and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
03/18/2025
Locations: Conestoga Eye, Lancaster, Pennsylvania
Conditions: Amblyopia
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.
Gender:
ALL
Ages:
Between 3 years and 13 years
Trial Updated:
03/18/2025
Locations: Conestoga Eye, Lancaster, Pennsylvania
Conditions: Amblyopia
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
Recruiting
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/17/2025
Locations: Penn Medicine Lancaster General Health, Lancaster, Pennsylvania
Conditions: Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
Pan Tumor Rollover Study
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Local Institution - 0400, Lancaster, Pennsylvania
Conditions: Cancer
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/10/2025
Locations: Lancaster General Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania +1 locations
Conditions: Breast Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Recruiting
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Urological Associates of Lancaster, Lancaster, Pennsylvania
Conditions: Biochemically Recurrent Prostate Cancer
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Recruiting
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Lancaster General Health - Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Cervical Cancer, Uterine Cancer, Endometrial Cancer
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Recruiting
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Non-small Cell Lung Cancer
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Site US10027, Lancaster, Pennsylvania
Conditions: Prostate Cancer
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
Recruiting
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
03/04/2025
Locations: Center for Interventional Pain and Spine, Lancaster, Pennsylvania
Conditions: Lumbar Spinal Stenosis